# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0001193125-26-100860
**Filing Date:** 2026-3
**Character Count:** 13991
**Document Hash:** 10f178c1bf7972af55f9432522cdb5f3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-100860.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001193125-26-100860

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294197
- **FILM NUMBER:** 26741409

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121

**As filed with the Securities and Exchange Commission on March 10, 2026.** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-3**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Dianthus Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-0724163** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**7 Times Square, 43rd Floor** 

**New York, NY 10036** 

**(929) 999-4055**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Ryan Savitz** 

**EVP, Chief Financial Officer and Chief Business Officer** 

**Dianthus Therapeutics, Inc.** 

**7 Times Square, 43rd Floor** 

**New York, NY 10036** 

**(929) 999-4055**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***With copies to:***

---

| | |
|:---|:---|
| **Ryan A. Murr**<br> **Branden C. Berns**<br> **Melanie E. Neary**<br> **Gibson, Dunn & Crutcher LLP**<br> **One Embarcadero Center, Suite 2600**<br> **San Francisco, CA 94111**<br> **(415) 393-8200** | **Adam M. Veness, Esq.**<br> **SVP, General Counsel and Secretary**<br> **Dianthus Therapeutics, Inc.**<br> **7 Times Square, 43rd Floor**<br> **New York, NY 10036**<br> **(929) 999-4055** |

---

**Approximate date of commencement of proposed sale to the public:** From time to time after this registration statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-293014

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION OF** 

**CERTAIN INFORMATION BY REFERENCE** 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Dianthus Therapeutics, Inc. (the "Registrant") is filing this Registration Statement on Form S-3 (this "Registration Statement") with the Securities and Exchange Commission (the "Commission"). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-293014) (the "Prior Registration Statement"), which the Registrant filed with the Commission on January 28, 2026, and which the Commission declared effective on January 30, 2026.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate amount of securities offered by the Registrant by a proposed aggregate offering price of $120,000,000, which includes shares that may be sold by the Registrant in the event the underwriters exercise their option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.

The required opinion and consents are listed on the Exhibit Index below and filed herewith or incorporated by reference herein.

------

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 16.** **Exhibits** <br>

All exhibits filed with or incorporated by reference in the Registration Statement on Form S-3 (File No. 333-293014) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 5.1 | [Opinion of Gibson, Dunn & Crutcher LLP (incorporated by reference to Exhibit 5.1 to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1690585/000119312526027273/d53438dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d115984dex231.htm) |
| 23.2 | [Consent of Gibson, Dunn & Crutcher LLP (see Exhibit 5.1).](http://www.sec.gov/Archives/edgar/data/1690585/000119312526027273/d53438dex51.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1690585/000119312526027273/d53438ds3.htm#sig) |
| 107 | [Filing Fee Table.](d115984dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 10, 2026.

---

| | |
|:---|:---|
| **Dianthus Therapeutics, Inc.** | **Dianthus Therapeutics, Inc.** |
| By: | /s/ Ryan Savitz |
|  | Ryan Savitz |
|  | EVP, Chief Financial Officer and |
|  | Chief Business Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signatures** | **Title** | **Date** |
| /s/ Marino Garcia<br> Marino Garcia | President, Chief Executive Officer and Director<br> (*Principal Executive Officer*) | March 10, 2026 |
| /s/ Ryan Savitz<br> Ryan Savitz | EVP, Chief Financial Officer and Chief Business Officer<br> *(Principal Financial Officer)* | March 10, 2026 |
| /s/ Edward Carr\*<br> Edward Carr | Chief Accounting Officer<br> *(Principal Accounting Officer)* | March 10, 2026 |
| /s/ Alison F. Lawton\*<br> Alison F. Lawton | Director and Chair of the Board | March 10, 2026 |
| /s/ Sujay Kango\*<br> Sujay Kango | Director | March 10, 2026 |
| /s/ Anne McGeorge\*<br> Anne McGeorge | Director | March 10, 2026 |
| /s/ Simon Read, Ph.D.\*<br> Simon Read, Ph.D. | Director | March 10, 2026 |
| /s/ Steven Romano, M.D.\*<br> Steven Romano, M.D. | Director | March 10, 2026 |
| /s/ Paula Soteropoulos\*<br> Paula Soteropoulos | Director | March 10, 2026 |
| /s/ Jonathan Violin, Ph.D.\*<br> Jonathan Violin, Ph.D. | Director | March 10, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Ryan Savitz |
|  | Ryan Savitz |
|  | *Attorney-in-fact* |

---

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 8, 2026 relating to the financial statements of Dianthus Therapeutics, Inc., appearing in the Annual Report on Form 10-K of Dianthus Therapeutics, Inc. for the year ended December 31, 2025. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Deloitte & Touche LLP

Morristown, New Jersey

March 10, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-3**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Dianthus Therapeutics, Inc. /DE/**  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
|  |  | Equity | Common Stock, $0.001 par value per share | 457(o) |  |  |  |
|  |  | Other | Warrants | 457(o) |  |  |  |
| Fees to be Paid | 1 | Unallocated (Universal) Shelf |  | 457(o) | $120000000.00 | 0.0001381 | $16572.00 |
| Fees Previously Paid |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $120000000.00  |  | $16572.00  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  |  | $16572.00  |

---

 **Offering Note** <br>

<sup>1</sup> The Registrant previously registered the offer and sale of certain securities, including its common stock, par value $0.001 per share, having a proposed maximum aggregate offering price of $600,000,000 pursuant to Registration Statement on Form S-3 (File No. 333-293014), which was filed on January 28, 2026 and declared effective by the SEC on January 30, 2026 (the "Prior Registration Statement"). As of the date hereof, a balance of $600,000,000 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant is hereby registering the offer and sale of an additional $120,000,000 of its shares of common stock. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Amount of Securities Previously Registered**  | **Maximum Aggregate Offering Price of Securities Previously Registered**  | **Form Type**  | **File Number**  | **Initial Effective Date**  |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---